Lates News

Every AI Express News, Cinda Securities released a research report on April 26th, giving a buy rating to Harbin Pharmaceutical Group (stock code: 600664.SH). The main reasons for the rating include: 1) The company is expected to reach a turning point in performance in 2024, with performance improvement mainly benefiting from operational improvements, which are sustainable; 2) The net profit margin of the industrial sector exceeded expectations in the first quarter of 2025, despite pressure on the commercial sector. (Daily Economic News)